黄芪注射液治疗脑梗塞后抑郁症32例疗效观察

目的：探讨黄芪注射液对比脑蛋白水解物治疗脑梗塞后抑郁症的疗效观察.方法：回顾性分析2012年5月-2013年8月期间因脑梗塞后抑郁症入院的患者64例,按计划分为两组,每组32例,分别予以黄芪注射液（观察组）和脑蛋白水解物（对照组）,比较两组患者治疗后临床效果、HAMD评分、SDS评分以及不良反应发生情况.结果：观察组显效率78.1%明显高于对照组43.8%,治疗后HAMD评分（16.1±4.3）明显低于对照组（25.2±4.0）,SDS评分（51.7±3.6）明显低于对照组（59.9±4.1）,总不良反应15.7%明显低于对照组31.3%.结论：黄芪注射液对于治疗脑梗塞后抑郁症临床疗效明显,HAMD评分和SDS评分下降显著,不良反应发生率低,适合临床广泛应用.

Clinical effective observation on treating post-celebral infarction depression with the Huangqi injection

Objective： To compare the curative effect between Huangqi injection and cerebroprotein hydrolysate on post-cerebral infarction depression. Methods： Retrospectively analyzing the clinical data of 64 patients with post-cerebral infarction depression from May 2012 to Aug. 2013 in our hospital. According to the plan, we divided them into 2 groups, with 32 cases in each group. One group was treated with Huangqi injection （observation group） , and another was given cerebroprotein hydrolysate （control group）. Then we analyzed and compared the clinical data of the two groups, including HAMD score, SDS score and adverse reaction. Results： The effective rate ofthe observation group （78.1%） is significantly higher than that in control group （43.8%） after treatment; HAMD score of the observation group （16.1±4.3） is lower than that in the control group （25.2±4.0）; SDS score of the observation group （51.7±3.6） is lower than that inthe control group （59.9±4.1）; the total adverse reaction rate of the observation group （15.7%） is significantly lower than the control group（31.3%）. Conclusion： Huangqi injection is more suitable for clinical application, for its good clinical curative effect, low HAMD score,SDS score and adverse reaction rate.